LLY241004C570000
- 311.40
- 0.000.00%
Eli Lilly and Co Newsroom
Tandem Diabetes Insulin Pump Demand to Surge Despite Popular Demand Of Weight Loss Drugs, Bullish Analyst Says
Eli Lilly Commits $4.5B To New Facility, Banking On Mounjaro, Zepbound's Weight Loss Success Despite Short-Term Stock Challenges
"Cash is king" is outdated, these assets are more worth buying.
The outlook for cash assets is becoming bleak, and a rate cut by the Federal Reserve will erode the yield of cash assets.
Bristol-Myers Tops Growth Chart Among S&P 500 Healthcare Stocks in Q3
Novo Nordisk Is Still a Buy, Analysts Say. Slowing Growth for Ozempic and Wegovy Isn't a Problem. -- Barrons.com
Eli Lilly (NYSE:LLY) Eyes Broader Market for Weight-Loss Drugs
Eli Lilly (LLY) Stock Price Prediction and Forecast 2025-2030
Express News | Eli Lilly and Co will invest 4.5 billion US dollars to build an Eli Lilly pharmaceutical factory
Express News | Eli Lilly and Co - Medicine Foundry Expected to Add 400 Full-Time Jobs
Express News | Eli Lilly and Co - Facility to Open in Late 2027, Increasing U.S. Capital Commitment to $23 Billion
Eli Lilly to Build $4.5 Billion Research and Manufacturing Center to Propel Drug Pipeline
Lilly Announces New $4.5 Billion Site - the Lilly Medicine Foundry - to Drive Innovation in Drug Production and Make Medicines for Clinical Trials
In September, influenced by the Federal Reserve's interest rate cut and optimistic sentiment towards ai, the technology market value soared.
Fed rate cuts typically boost future profits and cash flow for high-growth companies. With this boost, the market cap of many technology companies surged in September, further driven by the sustained enthusiasm for artificial intelligence. Tesla's market cap soared by 22.2% last month, reaching $834.4 billion by the end of September. This was mainly due to record-breaking electric car sales in China in August, as well as Tesla's plans to launch its Full Self-Driving (FSD) advanced driver assistance software in China and Europe. Oracle's market cap climbed by 21.3% at the end of last month, reaching $472.2 billion, the company
Eli Lilly and Co (LLY.US) explores new uses for 'weight-loss miracle drug' Zepbound, aiming to reduce the incidence of high-risk populations such as diabetes.
eli lilly and co is exploring new uses for its weight loss drug Zepbound to reduce the incidence of diabetes in high-risk populations, even if they are not overweight.
US HHS Reveal Cost Savings For 54 Prescription Drugs Including Novartis' Cancer Drug, Ozempic Could Be Next
Sector Update: Health Care Stocks Retreat Tuesday Afternoon
Port Strike Fallout: Blockbuster Weight-loss Drug Supply From Wegovy to Ozempic, Mounjaro, Zepbound Caught up in East Coast Trade Shutdown
Eli Lilly's Options: A Look at What the Big Money Is Thinking
Lilly Looking to Test Zepbound as Health Maintenance Drug: Report
Eli Lilly Aims To Expand Weight-Loss Drug Trials To Those At Risk, Not Just Overweight